Bayer's admission of 'mistake' underscores FDA's struggles

Share this article:
A Bayer admission that it "mistakingly" did not submit new risk information to the FDA on antibleeding drug Trasylol underscores the agency's struggle to get critical drug safety information out to the public. FDA had to replace a news release hours after it was issued to reflect new data.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions